Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
This oral care formulation is a combination of zinc chloride (0.6% w/w), isopropyl methylphenol (IPMP, 0.1% w/w), and sodium fluoride, developed by GSK for use in silica-based toothpastes. The active ingredients work synergistically to provide antimicrobial, anti-caries, and malodor-control benefits. Isopropyl methylphenol (also known as o-cymen-5-ol) is a phenolic antimicrobial agent that effectively penetrates dental biofilms to target plaque bacteria. Zinc chloride provides additional antimicrobial effects and neutralizes volatile sulfur compounds (VSCs) responsible for halitosis (bad breath). Sodium fluoride serves as the anti-caries agent by providing fluoride ions that promote enamel remineralization and increase acid resistance. The formulation is used to maintain gingival health, reduce dental plaque and gingival bleeding, and prevent tooth decay without compromising fluoride bioavailability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on zinc chloride + isopropyl methylphenol + sodium fluoride.